Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 3.64
SGYP's Cash-to-Debt is ranked higher than
52% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. SGYP: 3.64 )
Ranked among companies with meaningful Cash-to-Debt only.
SGYP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: No Debt Max: No Debt
Current: 3.64
Piotroski F-Score: 2
Altman Z-Score: -2.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -2804.71
SGYP's ROE % is ranked lower than
100% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. SGYP: -2804.71 )
Ranked among companies with meaningful ROE % only.
SGYP' s ROE % Range Over the Past 10 Years
Min: -2804.71  Med: -319.1 Max: -154.96
Current: -2804.71
-2804.71
-154.96
ROA % -179.72
SGYP's ROA % is ranked lower than
98% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. SGYP: -179.72 )
Ranked among companies with meaningful ROA % only.
SGYP' s ROA % Range Over the Past 10 Years
Min: -6858.53  Med: -154.23 Max: -69.97
Current: -179.72
-6858.53
-69.97
ROC (Joel Greenblatt) % -24077.73
SGYP's ROC (Joel Greenblatt) % is ranked lower than
98% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. SGYP: -24077.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGYP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -423053.33  Med: -74545.45 Max: -15317.3
Current: -24077.73
-423053.33
-15317.3
3-Year EBITDA Growth Rate 6.50
SGYP's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. SGYP: 6.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGYP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 21.55 Max: 131.7
Current: 6.5
0
131.7
3-Year EPS without NRI Growth Rate 18.30
SGYP's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. SGYP: 18.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGYP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 24.6 Max: 122.4
Current: 18.3
0
122.4
GuruFocus has detected 3 Warning Signs with Synergy Pharmaceuticals Inc $SGYP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SGYP Guru Trades in Q1 2016

Paul Tudor Jones 48,161 sh (+118.18%)
John Paulson 11,090,000 sh (+23.22%)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
» More
Q2 2016

SGYP Guru Trades in Q2 2016

John Paulson 27,756,668 sh (+150.29%)
Paul Tudor Jones 34,385 sh (-28.60%)
» More
Q3 2016

SGYP Guru Trades in Q3 2016

John Paulson 24,228,655 sh (-12.71%)
Paul Tudor Jones 18,144 sh (-47.23%)
» More
Q4 2016

SGYP Guru Trades in Q4 2016

Paul Tudor Jones 18,376 sh (+1.28%)
John Paulson 24,088,655 sh (-0.58%)
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
Traded in other countries:S90.Germany,
Synergy Pharmaceuticals Inc is a biopharmaceutical company. It engages in the development of drugs to treat gastrointestinal, or GI, disorders and diseases.

Synergy Pharmaceuticals Inc was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.

Top Ranked Articles about Synergy Pharmaceuticals Inc

John Paulson Trims Synergy Company is among many drug manufacturers in portfolio
John Paulson (Trades, Portfolio) of Paulson & Co. reduced his holdings in Synergy Pharmaceuticals (NASDAQ:SGYP) by 12.5% on Sept. 19. Read more...

Ratios

vs
industry
vs
history
PB Ratio 25.17
SGYP's PB Ratio is ranked lower than
97% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. SGYP: 25.17 )
Ranked among companies with meaningful PB Ratio only.
SGYP' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 28.7
Current: 25.17
0
28.7
Current Ratio 3.02
SGYP's Current Ratio is ranked higher than
60% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. SGYP: 3.02 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 4.59 Max: 10.92
Current: 3.02
0.13
10.92
Quick Ratio 2.83
SGYP's Quick Ratio is ranked higher than
67% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. SGYP: 2.83 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 4.59 Max: 10.92
Current: 2.83
0.13
10.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -31.00
SGYP's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. SGYP: -31.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGYP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -248.4  Med: -23.15 Max: -14.6
Current: -31
-248.4
-14.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 31.07
SGYP's Price-to-Net-Cash is ranked lower than
78% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.85 vs. SGYP: 31.07 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGYP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 9.91  Med: 26.62 Max: 92
Current: 31.07
9.91
92
Price-to-Net-Current-Asset-Value 25.89
SGYP's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. SGYP: 25.89 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGYP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.1  Med: 23.07 Max: 73.6
Current: 25.89
9.1
73.6
Price-to-Tangible-Book 24.53
SGYP's Price-to-Tangible-Book is ranked lower than
95% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. SGYP: 24.53 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGYP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 9.04  Med: 19.12 Max: 65.33
Current: 24.53
9.04
65.33
Earnings Yield (Greenblatt) % -14.83
SGYP's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. SGYP: -14.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGYP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.76  Med: 0 Max: 680.5
Current: -14.83
-15.76
680.5

More Statistics

EPS (TTM) $ -1.28
Beta1.63
Short Percentage of Float31.46%
52-Week Range $2.60 - 7.15
Shares Outstanding (Mil)223.12

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 34 155 226
EPS ($) -0.48 0.01 0.26
EPS without NRI ($) -0.48 0.01 0.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
John Paulson Trims Synergy Sep 23 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 

More From Other Websites
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for... Mar 30 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 27 2017
Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for TRULANCE™... Mar 27 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 21 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 14 2017
Synergy Pharmaceuticals to Present at Oppenheimer 27th Annual Healthcare Conference Mar 14 2017
SYNERGY PHARMACEUTICALS, INC. Financials Mar 07 2017
CORRECTING and REPLACING Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial... Mar 02 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 02 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 01 2017
Synergy Pharma reports 4Q loss Mar 01 2017
Synergy Pharma reports 4Q loss Mar 01 2017
Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business... Mar 01 2017
Did 50 Salespeople Leave Valeant? Wells Fargo Investigates Feb 23 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 15 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 08 2017
Synergy Pharmaceuticals to Present at Leerink Partners 6th Annual Global Healthcare Conference Feb 08 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 07 2017
Pivotal Phase 3 Data Results for TRULANCE™ (plecanatide) in the Treatment of Chronic Idiopathic... Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)